

Roberto Marchioli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1050828/publications.pdf>

Version: 2024-02-01

117
papers

14,393
citations

61984

43
h-index

23533

111
g-index

121
all docs

121
docs citations

121
times ranked

14232
citing authors

#	ARTICLE	IF	CITATIONS
1	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, The, 2010, 375, 735-742.	13.7	2,064
2	Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction. Circulation, 2002, 105, 1897-1903.	1.6	1,213
3	Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 1231-1239.	13.7	954
4	Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. New England Journal of Medicine, 2004, 350, 114-124.	27.0	911
5	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. New England Journal of Medicine, 2013, 368, 22-33.	27.0	664
6	Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera. Journal of Clinical Oncology, 2005, 23, 2224-2232.	1.6	631
7	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	13.7	562
8	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA Cardiology, 2018, 3, 225.	6.1	526
9	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	13.7	512
10	n-3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors. New England Journal of Medicine, 2013, 368, 1800-1808.	27.0	464
11	Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 2005, 105, 2664-2670.	1.4	389
12	Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 2007, 109, 2446-2452.	1.4	356
13	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 2008, 93, 372-380.	3.5	316
14	Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood, 2007, 109, 2310-2313.	1.4	295
15	Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1368-1377.	2.4	287
16	Omega-3 Fatty Acids for Cardioprotection. Mayo Clinic Proceedings, 2008, 83, 324-332.	3.0	218
17	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure, 2004, 6, 635-641.	7.1	214
18	Fish Oil and Postoperative Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2012, 308, 2001.	7.4	201

#	ARTICLE	IF	CITATIONS
19	A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. American Heart Journal, 2007, 153, 1037-1047.	2.7	200
20	The haematocrit and platelet target in polycythemia vera. British Journal of Haematology, 2007, 136, 249-259.	2.5	162
21	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica, 2011, 96, 315-318.	3.5	160
22	Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet, The, 2007, 370, 667-675.	13.7	153
23	Aspirin Therapy in Primary Cardiovascular Disease Prevention. Journal of the American College of Cardiology, 2014, 64, 319-327.	2.8	150
24	Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 277-283.	2.8	147
25	The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI heart failure (GISSI-HF) trial. European Journal of Heart Failure, 2010, 12, 338-347.	7.1	129
26	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 2015, 36, 1536-1546.	2.2	126
27	Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. American Heart Journal, 2010, 159, 245-257.	2.7	106
28	Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. European Journal of Heart Failure, 2005, 7, 904-909.	7.1	101
29	Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure. Circulation: Heart Failure, 2010, 3, 65-72.	3.9	101
30	Predictors of Mortality in 6975 Patients With Chronic Heart Failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure Trial. Circulation: Heart Failure, 2013, 6, 31-39.	3.9	101
31	Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. European Heart Journal, 2009, 30, 2327-2336.	2.2	98
32	Cholesterol Reduction and Stroke Occurrence: An Overview of Randomized Clinical Trials. Cerebrovascular Diseases, 2000, 10, 85-92.	1.7	97
33	Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. Journal of Cardiovascular Medicine, 2006, 7, 347-350.	1.5	96
34	Cholesterol-Lowering Interventions and Stroke. Journal of the American College of Cardiology, 2010, 55, 198-211.	2.8	88
35	Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. European Journal of Heart Failure, 2010, 12, 1345-1353.	7.1	75
36	Diet and gallstones in Italy: The cross-sectional MICOL results. Hepatology, 1998, 27, 1492-1498.	7.3	70

#	ARTICLE	IF	CITATIONS
37	Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. European Journal of Clinical Pharmacology, 2004, 60, 183-190.	1.9	68
38	European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): A Randomized Trial. Seminars in Thrombosis and Hemostasis, 1997, 23, 473-478.	2.7	64
39	Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. European Journal of Heart Failure, 2012, 14, 1410-1419.	7.1	64
40	Coffee Consumption and Risk of Cardiovascular Events After Acute Myocardial Infarction. Circulation, 2007, 116, 2944-2951.	1.6	55
41	Fish Oil and Post-Operative Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2194-2196.	2.8	52
42	Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. Current Cardiology Reports, 2000, 2, 293-299.	2.9	51
43	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology, 2017, 136, 128-137.	1.4	46
44	Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial. Journal of the American Heart Association, 2015, 4, .	3.7	43
45	Wine consumption and risk of cardiovascular events after myocardial infarction: Results from the GISSI-Prevenzione trial. International Journal of Cardiology, 2013, 163, 282-287.	1.7	42
46	Meta-Analysis of Effect of Statin Treatment on Risk of Sudden Death. American Journal of Cardiology, 2007, 100, 1644-1650.	1.6	41
47	Uric acid: A cardiovascular risk factor in patients with recent myocardial infarction. International Journal of Cardiology, 2013, 167, 262-269.	1.7	41
48	A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis.. Blood, 2007, 110, 3540-3540.	1.4	39
49	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. Expert Review of Cardiovascular Therapy, 2009, 7, 735-748.	1.5	37
50	Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. International Journal of Cardiology, 2014, 172, 403-410.	1.7	36
51	Fish Oil and Perioperative Bleeding. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004584.	2.2	36
52	Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 242-251.e10.	0.8	34
53	n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. European Journal of Heart Failure, 2013, 15, 1289-1295.	7.1	33
54	Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. European Heart Journal, 2007, 28, 1977-1983.	2.2	31

#	ARTICLE	IF	CITATIONS
55	The ï‰-3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trialâ€™ rationale and design. American Heart Journal, 2011, 162, 56-63.e3.	2.7	31
56	Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardicoâ€™Heart Failure trial. Nutrition Research, 2016, 36, 989-994.	2.9	30
57	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza) Tj ETQq1 1 0.784314 rgBT /Overl 205-215.	3.4	30
58	Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2543-2551.	1.3	29
59	GISSI-Prevenzione trial. Lancet, The, 1999, 354, 1556-1557.	13.7	26
60	BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. British Journal of Haematology, 1997, 99, 379-385.	2.5	24
61	Plasma Phospholipid Omegaâ€™3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial. Journal of the American Heart Association, 2013, 2, e000397.	3.7	24
62	n-3PUFA and Holter-derived autonomic variables in patients with heart failure: Data from the Gruppo Italiano per lo Studio della Sopravvivenza nellâ€™Insufficienza Cardiaca (GISSI-HF) Holter substudy. Heart Rhythm, 2013, 10, 226-232.	0.7	23
63	Circulating cardiac biomarkers and postoperative atrial fibrillation in the <scp>OPERA</scp> trial. European Journal of Clinical Investigation, 2015, 45, 170-178.	3.4	23
64	Family history and socioeconomic factors as predictors of myocardial infarction, unstable angina and stroke in an Italian population. European Journal of Epidemiology, 1996, 12, 177-185.	5.7	22
65	Omega-3 fatty acids and heart failure. Current Atherosclerosis Reports, 2009, 11, 440-447.	4.8	22
66	nâ€™3 PUFAs in cardiovascular disease. International Journal of Cardiology, 2013, 170, S33-S38.	1.7	21
67	Polycythemia vera: gender-related phenotypic differences. Internal and Emergency Medicine, 2012, 7, 509-515.	2.0	19
68	A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).. Blood, 2009, 114, 754-754.	1.4	19
69	Phase I/II study of singleâ€™agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology, 2010, 85, 616-619.	4.1	18
70	Prognostic impact of metabolic syndrome in patients with chronic heart failure: Data from GISSI-HF trial. International Journal of Cardiology, 2015, 178, 85-90.	1.7	18
71	Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT. Atherosclerosis, 2016, 248, 216-218.	0.8	18
72	Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. Vascular Health and Risk Management, 2006, 2, 507-514.	2.3	18

#	ARTICLE	IF	CITATIONS
73	Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. Pulmonary Pharmacology and Therapeutics, 2017, 44, 16-23.	2.6	16
74	Cardiovascular risk changes after lipid lowering medications: are they predictable?. Atherosclerosis, 2000, 152, 1-8.	0.8	14
75	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins â€” Confirmation from PCSK9 Inhibitor Studies. American Journal of Medicine, 2020, 133, 95-99.e6.	1.5	14
76	Analysis of the Benefits of a Mediterranean Diet in the GISSI-Prevenzione Study: A Case Study in Imputation of Missing Values from Repeated Measurements. European Journal of Epidemiology, 2006, 21, 15-24.	5.7	12
77	A low plasma 1,25(OH) 2 vitamin D/PTH (1â€”84) ratio predicts worsening of renal function in patients with chronic heart failure. International Journal of Cardiology, 2016, 224, 220-225.	1.7	12
78	Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. Haematologica, 2013, 98, 1421-1423.	3.5	11
79	A Positive Relation between High Hemoglobin Values and the Risk of Ischemic Stroke. European Neurology, 1996, 36, 85-88.	1.4	10
80	Clinical Trials in Myeloproliferative Disorders: Looking Forward. Seminars in Hematology, 2005, 42, 259-265.	3.4	9
81	n-3 PUFAs and heart failure. International Journal of Cardiology, 2013, 170, S28-S32.	1.7	9
82	Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma. British Journal of Haematology, 1997, 96, 620-626.	2.5	8
83	Hypertension Optimal Treatment (HOT) trial. Lancet, The, 1998, 352, 571-572.	13.7	8
84	Cancer in chronic heart failure patients in the GISSIâ€”HF trial. European Journal of Clinical Investigation, 2020, 50, e13273.	3.4	8
85	Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses â€” First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. Blood, 2012, 120, 550-550.	1.4	8
86	Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. Haematologica, 2005, 90, 851-3.	3.5	8
87	Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. Journal of Multidisciplinary Healthcare, 2010, 3, 79.	2.7	7
88	Modes of death and prognostic outliers in chronic heart failure. American Heart Journal, 2019, 208, 100-109.	2.7	7
89	A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results. Blood, 2010, 116, 314-314.	1.4	7
90	Prospective Evaluation of Clinico-Pathological Predictors of Postoperative Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008382.	4.8	6

#	ARTICLE	IF	CITATIONS
91	Fish Oil Supplementation Does Not Affect Cognitive Outcomes in Cardiac Surgery Patients in the Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) Trial. Journal of Nutrition, 2018, 148, 472-479.	2.9	5
92	IGENDA protocol: gender differences in awareness, knowledge and perception of cardiovascular risk: An Italian multicenter study. Journal of Cardiovascular Medicine, 2019, 20, 278-283.	1.5	5
93	Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects. Thrombosis and Haemostasis, 2002, 87, 58-67.	3.4	5
94	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. Blood, 2013, 122, 1583-1583.	1.4	4
95	Prognosis of Veno-Occlusive Disease after Stem Cell Transplantation in the DF-VOD Trial. On behalf of the DF-VOD Investigators:... Blood, 2004, 104, 1137-1137.	1.4	4
96	Chronic infections and coronary heart disease. Lancet, The, 1997, 350, 1028-1029.	13.7	3
97	Global cardiovascular risk evaluation. Journal of Cardiovascular Medicine, 2016, 17, 581-586.	1.5	3
98	A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). Blood, 2012, 120, 4-4.	1.4	3
99	Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL). Blood, 2012, 120, 746-746.	1.4	3
100	Clinical Significance of JAK2V617F Homozygosity in the Chronic Myeloproliferative Disorders. A Study on 1306 Patients.. Blood, 2006, 108, 664-664.	1.4	3
101	Why Do We Still Need Large Scale Clinical Trial: The Case of nâ”³ PUFA. Frontiers in Physiology, 2012, 3, 202.	2.8	2
102	Fish Oil vs Olive Oil for Postoperative Atrial Fibrillationâ”Reply. JAMA - Journal of the American Medical Association, 2013, 309, 871.	7.4	2
103	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. Blood, 2011, 118, 1750-1750.	1.4	2
104	Correlation of Novel Molecular Markers in Patients with Myeloproliferative Neoplasms.. Blood, 2009, 114, 4968-4968.	1.4	2
105	The yield of meta-analysis. Lancet, The, 1998, 351, 915-916.	13.7	1
106	Current Treatment Approaches of Polycythemia Vera. Clinical Leukemia, 2006, 1, 41-45.	0.2	1
107	Corrigendum to â”Effects of n -3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trialâ”™ [Eur J Heart Fail 2010;12:1345-1353]. European Journal of Heart Failure, 2011, 13, 1042-1042.	7.1	1
108	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. Data in Brief, 2016, 7, 1541-1550.	1.0	1

#	ARTICLE	IF	CITATIONS
109	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. Blood, 2012, 120, 1748-1748.	1.4	1
110	Leukocytosis as an Independent Risk Factor for Thrombosis in Polycythemia Vera.. Blood, 2006, 108, 115-115.	1.4	1
111	A GITIL Prospective Randomized Multicenter Phase III Study of High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Transplantation (ASCT) of Peripheral Blood Stem Cells Versus CHOP and Rituximab Delivered Every 14 Days (R-CHOP-14) in High-Risk Patients with Diffuse Large B-Cell Lymphomas (DLBCL): Interim Analysis on Feasibility and Toxicity (Protocol R-HDS 0305).. Blood, 2007, 110, 1898-1898.	1.4	1
112	Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07. Blood, 2010, 116, 2131-2131.	1.4	1
113	Are All Fish Equally Close to the Heart?â€“Reply. Mayo Clinic Proceedings, 2008, 83, 724-725.	3.0	0
114	High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.. Blood, 2009, 114, 1220-1220.	1.4	0
115	In Vivo T Cell Depletion with Antithymocyte Globulin or Alemtuzumab for Unrelated Donor Stem Cell Transplantation with Reduced Intensity Conditioning: Results of a Multicenter Randomized Phase II Clinical Trial (The Global Study) From the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Blood, 2012, 120, 221-221.	1.4	0
116	Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte®) In Adult Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 3901-3901.	1.4	0
117	Abstract 12364: Circulating Cardiac and Inflammatory Biomarkers to Predict Post-Operative Atrial Fibrillation in the OPERA Trial. Circulation, 2014, 130, .	1.6	0